IVZ injections improve eyes with non-AMD-related choroidal neovascularization
Treatment with intravitreal ziv-aflibercept (IVZ) injections improves central macular thickness (CMT) in patients with choroidal neovascularization (CNV) associated with causes other than age-related macular degeneration (AMD), a recent study has found. However, improvements in best-corrected visual acuity (BCVA) are modest.
In this retrospective study, researchers included eyes with non-AMD-related CNV that were treated with IVZ (1.25 mg/0.05 mL) on a pro re nata basis. The mean change in BCVA was the primary outcome measure, and the secondary outcome measures were the mean change in CMT and adverse events.
A total of 23 eyes of 19 patients with CNV received treatment with IVZ injections. The causes of CNV were as follows: high myopia (9), macular telangiectasia (4), central serous chorioretinopathy (3), choroidal osteoma (2), choroiditis (2), Best’s disease (2) and idiopathic (1).
During a mean follow-up period of 4±1.9 months, the median number of IVZ infections was 1 (range, 1 to 3) and the median treatment-free interval at the time of the final visit was 3 months (range, 1 to 8).
Mean BCVA improved from 0.67 LogMAR to 0.58 LogMAR (p=0.0507). Of the 23 eyes, nine (39 percent) had BCVA improvements of at least 0.1 LogMAR, 11 (48 percent) had stable BCVA (within 0.1 LogMAR of baseline) and three (13 percent) had a BCVA decline of at least 0.1 LogMAR at the final visit. From baseline until the final visit, the mean CMT significantly improved (22 vs 174.5 μm; p=0.037).
There were no ocular or systemic adverse events recorded, according to researchers.